Keros Therapeutics, Inc. (NASDAQ: KROS) director Nima Farzan has executed a sale of 2,625 shares of the company's common stock, resulting in proceeds of approximately $28,166. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which was established on December 5, 2025. This structured approach to selling stock is typically designed to avoid allegations of insider trading by predetermining the terms of the transaction in advance.
The sale took place on June 4, 2026, and occurred while the company's shares were trading near their 52-week low of $9.79. The shares were sold at prices ranging from $10.61 to $10.89 per share. The timing is notable as the stock has declined 52% over the past six months. Despite this weakness, InvestingPro analysis suggests the stock is undervalued at current levels, appearing on the platform's most undervalued stocks list. Following these sales, Mr. Farzan directly owns 9,767 shares of Keros Therapeutics common stock.
For investors seeking deeper insights, InvestingPro offers 11 additional ProTips and comprehensive financial metrics to help evaluate KROS's investment potential. This report was filed with the Securities and Exchange Commission on June 8, 2026.